Search results for "Heparin"

showing 10 items of 191 documents

Topical Issues in Venous Thromboembolism

2010

Despite clear guidelines and the availability of effective treatments, venous thromboembolism (VTE) remains relatively common, particularly in the hospital setting. This paper reviews topical issues in VTE, in terms of treatments, data and guidelines. Existing anticoagulants have several limitations. Bleeding risk is a concern with all anticoagulants. Vitamin K antagonists are the mainstay of oral anticoagulant therapy, but they are limited by the need for frequent monitoring. Unfractionated heparin (UFH) is limited by an inconvenient route of administration (continuous intravenous infusion) and a higher risk of heparin-induced thrombocytopenia and bleeding compared with low molecular weigh…

Adultmedicine.medical_specialtyBlood Loss SurgicalVenographyFondaparinuxRoute of administrationPharmacotherapymedicineHumansPharmacology (medical)DosingChildIntensive care medicineSocieties Medicalmedicine.diagnostic_testbusiness.industryAnticoagulantsVenous ThromboembolismHeparinmedicine.diseaseUnited StatesClinical trialVenous thrombosisClinical AlarmsPractice Guidelines as TopicDrug Monitoringbusinessmedicine.drugDrugs
researchProduct

Evaluation of the Stratus® CS Acute Care™ D-dimer assay (DDMR) using the Stratus® CS STAT Fluorometric Analyzer: A prospective multisite study for ex…

2012

Abstract Background D-dimer testing is an integral part of the diagnostic algorithm in excluding patients with venous thromboembolism. In this study, we prospectively evaluated the Stratus DDMR D-dimer test in patients suspected of pulmonary embolism (PE) and deep vein thrombosis (DVT). Methods Patients suspected of venous thromboembolism were prospectively enrolled at four different clinical sites, with sodium citrate and lithium heparin plasma was tested using the DDMR D-dimer test on the Stratus CS analyzer. Results 1,012 patients were enrolled for analysis, with 85/603 (14.1%) patients with PE and 80/443 (18.1%) with DVT, and four of the patients (0.4%) with PE and DVT. For the samples …

Adultmedicine.medical_specialtyDeep veinGastroenterologyD-dimer assayFibrin Fibrinogen Degradation ProductsYoung AdultInternal medicineAcute caremedicineHumansFluorometryProspective Studiescardiovascular diseasesProspective cohort studyAgedAged 80 and overImmunoassayVenous Thrombosisbusiness.industryHematologyHeparinMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structurePulmonary EmbolismbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Thrombolysis for massive pulmonary embolism in pregnancy: a case report

2011

Adultmedicine.medical_specialtyPregnancyHeparinbusiness.industrymedicine.medical_treatmentPregnancy Complications CardiovascularGeneral MedicineThrombolysismedicine.diseasePulmonary embolismFibrinolytic AgentsPregnancyTissue Plasminogen Activatorpulmonary embolism prenancyEmergency MedicinemedicineHumansFemaleThrombolytic TherapyPulmonary EmbolismIntensive care medicinebusinessThe American Journal of Emergency Medicine
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct

Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study

2020

Background: Coronavirus disease 19 (COVID-19) is a global outbreak. COVID-19 patients seem to have relevant coagulative abnormalities, even if they are not typical of disseminated intravascular coagulopathy (DIC) of the kind seen in septicaemia. Therefore, anticoagulant therapy with heparins is increasing in interest for a clinical approach to these patients, particularly if older. Studies comparing if prophylactic doses are more effective than therapeutic ones are still missing. Methods: Data were collected in the Geriatric Section of the Dolo Hospital, ULSS 3 “Serenissima”, Venice from 31st March to 01st May 2020. Heparins (calciparin, fondaparinux, enoxaparine) were divided into prophyla…

Agingmedicine.medical_specialtyCOVID-19 · Heparin · Mortality.Short CommunicationDiseaseFondaparinux03 medical and health sciences0302 clinical medicineInternal medicinemedicineCoagulopathyHumans030212 general & internal medicineMortalitySurvival rateAgedRetrospective StudiesAged 80 and overHeparinSARS-CoV-2business.industryConfoundingHazard ratioAnticoagulantsCOVID-19Retrospective cohort studymedicine.diseaseConfidence intervalFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgerymedicine.drugAging Clinical and Experimental Research
researchProduct

Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium

2001

Background—Complement activation during reperfusion of ischemic myocardium augments myocardial injury, and complement inhibition with C1-esterase inhibitor (C1-INH) at the time of reperfusion exerts marked cardioprotective effects in experimental studies. Application of C1-INH in newborns, however, was recently reported to have dangerous and even lethal side effects. This study addresses the essential role of dosage in studies using C1-INH.Methods and Results—Cardioprotection by C1-INH was examined in a pig model with 60 minutes of coronary occlusion followed by 120 minutes of reperfusion. C1-INH was administered intravenously 5 to 10 minutes before coronary reperfusion without heparin at a…

Anaphylatoxinsmedicine.medical_specialtyNecrosisSwineHeart VentriclesPartial PressureMyocardial IschemiaIschemiaComplement C1 Inactivator ProteinsPharmacologyNecrosisTroponin TCoronary CirculationPhysiology (medical)Internal medicineAnimalsMedicineLactic AcidMyocardial infarctionCardiac OutputCreatine KinaseCardioprotectionDose-Response Relationship Drugbiologybusiness.industryMyocardiumHemodynamicsHeparinmedicine.diseaseComplement systemOxygenMicroscopy ElectronEndocrinologyCoronary occlusionEnzyme inhibitorReperfusion Injurybiology.proteinBlood Gas Analysismedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes.

2011

Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre) with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre(+/-), iDTR(+/-) offspring with DT to selectively destroy the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated Cre(-/-), iDTR(+/-) mice were used as GH-intact controls. AOiGHD im…

Anatomy and PhysiologyMousemedicine.medical_treatmentgh deficiencyMiceEndocrinology0302 clinical medicinefactor-iInsulinglucoseAge of OnsetInsulin-Like Growth Factor I2. Zero hunger0303 health scienceseducation.field_of_studyMultidisciplinarypancreatic beta-cellQRAnimal ModelsGHreceptor genehypothalamic expressionmedicine.anatomical_structureCarbohydrate MetabolismIntercellular Signaling Peptides and ProteinsMedicineincreased insulin sensitivityResearch ArticleHeparin-binding EGF-like Growth Factormedicine.medical_specialtymicediet-induced obesityDisfunción metabólicaSomatotropic cellSciencePopulationEndocrine System030209 endocrinology & metabolismBiologyCarbohydrate metabolismGrowth hormone deficiency03 medical and health sciencesModel OrganismsInsulin resistanceAnterior pituitaryreplacement therapyPituitary Gland AnteriorGrowth FactorsInternal medicinemedicineAnimalsObesityeducationBiologyNutrition030304 developmental biologyDiabetic EndocrinologyEndocrine PhysiologyInsulinDiabetes Mellitus Type 2Metabolyc disfunctionmedicine.diseaseHormonesMice Mutant StrainsSomatotrophsProlactinDietRatsDisease Models AnimalEndocrinologyPituitaryGrowth HormoneInsulin ResistanceEnergy IntakeEnergy MetabolismGHDPLoS ONE
researchProduct

Factors influencing the interaction of herpes simplex virus glycoprotein C with the third component of complement.

1992

The factors influencing the interaction of herpes simplex virus (HSV) glycoprotein C (gC) with the third component of complement (C3) were investigated in this study. The ability of gC of HSV type 1 (gC-1) to bind to the C3b fragment of C3 was found to be influenced by cell specific processing of gC-1 in a different manner, binding being remarkably enhanced in some cell lines following removal of sialic acid residues. Testing several intertypic recombinants of HSV we found that only strains expressing gC-1 exhibited binding to C3b, even though their genome consisted mainly of HSV-2 sequences in some recombinants. Expression of type-2 glycoproteins gB, gD, gE, gG, gH, and gI did not alter th…

AnionsRosette FormationMolecular Sequence DataBiologyIn Vitro Techniquesmedicine.disease_causeViruschemistry.chemical_compoundStructure-Activity RelationshipViral Envelope ProteinsVirologymedicineTumor Cells CulturedAnimalsHumansSimplexvirusAmino Acid SequenceVero Cellschemistry.chemical_classificationHeparinTemperatureGeneral MedicineNeomycinHerpesvirus glycoprotein BVirologySialic acidHerpes simplex viruschemistryComplement C3bVero cellbiology.proteinAntibodyGlycoproteinmedicine.drugProtein BindingArchives of virology
researchProduct

Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients

2014

Dyslipidemias may account for the excess of cardiovascular mortality in end-stage renal disease (ESRD). Lipoprotein studies in ESRD patients are usually relative to prehemodialysis samples even if significative changes may occur after dialysis. In this study, we aimed to investigate the effects of ESRD on triglyceride-rich lipoproteins (TRL) subpopulations distribution and acute change following hemodialytic procedures, including the relative contribution of heparin administration. We selected a group of normolipidemic male middle-aged ESRD patients free of any concomitant disease affecting lipoprotein remnant metabolism compared with controls. We separated TRL subfractions according to den…

Apolipoprotein Emedicine.medical_specialtyTriglyceridebusiness.industrymedicine.medical_treatmentHematologyHeparinEnd stage renal diseasechemistry.chemical_compoundEndocrinologychemistryNephrologyConcomitantInternal medicineMedicinelipids (amino acids peptides and proteins)HemodialysisbusinessDialysismedicine.drugLipoproteinHemodialysis International
researchProduct